HRP20160373T1 - Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava - Google Patents

Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava Download PDF

Info

Publication number
HRP20160373T1
HRP20160373T1 HRP20160373TT HRP20160373T HRP20160373T1 HR P20160373 T1 HRP20160373 T1 HR P20160373T1 HR P20160373T T HRP20160373T T HR P20160373TT HR P20160373 T HRP20160373 T HR P20160373T HR P20160373 T1 HRP20160373 T1 HR P20160373T1
Authority
HR
Croatia
Prior art keywords
use according
combination
physiologically acceptable
pharmaceutical
treatment
Prior art date
Application number
HRP20160373TT
Other languages
English (en)
Inventor
Joachim Maus
Beatrix Fyrnys
Torsten Hoffmann
Mario Weingart
Istvan Szelenyi
Peter Jürgen Cnota
Ullrich Munzel
Ursula Petzold
Original Assignee
Meda Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co. Kg filed Critical Meda Pharma Gmbh & Co. Kg
Publication of HRP20160373T1 publication Critical patent/HRP20160373T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Kombinacija R,R-glikopirolata ili njegove fiziološki prihvatljive soli i montelukasta ili njegove fiziološki prihvatljive soli, naznačena time, da se rabi u liječenju respiratornih bolesti, uključujući alergijski rinitis, bronhijalnu astmu, COPD ili prehladu.
2. Kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da je dnevna doza inhibitora leukotriena od 1 do 100 mg, poželjno od 5 do 20 mg.
3. Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je dnevna doza R,R-gliko pirolata od 1 do 500 µg.
4. Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je dnevna doza R,R-glikopirolata od 5 do 100 µg.
5. Farmaceutsko sredstvo za uporabu u liječenju respiratornih bolesti, uključujući alergijski rinitis, bronhijalnu astmu, COPD ili prehladu, naznačeno time, da sadržava R,R-glikopirolat ili njegove fiziološki prihvatljive soli i montelukast ili njegove fiziološki prihvatljive soli.
6. Farmaceutsko sredstvo za uporabu u skladu s patentnim zahtjevom 5, naznačeno time, da su aktivne tvari dostupne već pomiješane u određenoj kombinaciji, prema potrebi zajedno s uobičajenim nosačima, pomoćnim tvarima i dodacima, u farmaceutskom obliku prikladnom za inhalacijsku primjenu.
7. Farmaceutsko sredstvo za uporabu u skladu s patentnim zahtjevom 5, naznačeno time, da su dostupne aktivne tvari u zasebnim pakirnim jedinicama, pri čemu se obje supstance mogu uzeti iz zasebnih pakirnih jedinica na takav način, da su na raspolaganju za istovremenu inhalacijsku primjenu.
8. Farmaceutsko sredstvo za uporabu u skladu s patentnim zahtjevom 7, naznačeno time, da se aktivne tvari mogu primjenjivati nezavisno jedna od druge.
9. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačeno time, da je to inhalacijski aerosol sa ili bez potisnog plina.
10. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačeno time, da je to inhalacijski suhi prah.
11. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačeno time, da je to inhalacijska suspenzija ili otopina.
12. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 11, naznačeno time, da se nalazi u inhalatoru,
13. Uporaba R,R-glikopirolata ili njegovih fiziološki prihvatljivih soli i montelukasta ili njegovih fiziološki prihvatljivih soli za proizvodnju lijeka za liječenje respiratornih bolesti uključujući alergijski rinitis, bronhijalnu astmu, COPD ili prehladu kod sisavaca.
14. Uporaba u skladu s patentnim zahtjevom 13, naznačena time, da su sisavci mačke, psi, ili konji.
15. Uporaba u skladu s patentnim zahtjevom 13, naznačena time, da su bolesti karakterizirane opstruktivnim komponentama ili uzrokovane upalom poput astme i kronične opstruktivne plućne bolesti (KOPB).
HRP20160373TT 2005-03-16 2016-04-12 Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava HRP20160373T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
PCT/EP2006/002247 WO2006097250A1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases
EP06723360.1A EP1863476B1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
HRP20160373T1 true HRP20160373T1 (hr) 2016-05-06

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160373TT HRP20160373T1 (hr) 2005-03-16 2016-04-12 Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava

Country Status (19)

Country Link
US (1) US8268864B2 (hr)
EP (1) EP1863476B1 (hr)
JP (1) JP4991693B2 (hr)
CN (1) CN101128196B (hr)
AU (1) AU2006224842B2 (hr)
CA (1) CA2595791C (hr)
CY (1) CY1117571T1 (hr)
DK (1) DK1863476T3 (hr)
ES (1) ES2570332T3 (hr)
HK (1) HK1114013A1 (hr)
HR (1) HRP20160373T1 (hr)
HU (1) HUE027076T2 (hr)
MX (1) MX2007011273A (hr)
NO (1) NO340405B1 (hr)
NZ (1) NZ560206A (hr)
PL (1) PL1863476T3 (hr)
RU (1) RU2420285C2 (hr)
SI (1) SI1863476T1 (hr)
WO (1) WO2006097250A1 (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
EP1660491B1 (en) * 2003-07-28 2008-08-06 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
CA2702830C (en) 2007-10-18 2017-02-28 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
MX2010004529A (es) * 2007-10-25 2010-05-10 Merck Frosst Canada Ltd Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
CA2902795C (en) 2013-02-28 2021-06-15 Dermira, Inc. Glycopyrrolate salts
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
WO2014152229A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品
JP7314421B2 (ja) * 2020-02-03 2023-07-25 タロー・ファーマシューティカル・インダストリーズ・リミテッド 局所用モンテルカスト製剤
CN115792229A (zh) * 2022-01-28 2023-03-14 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
CA2165192C (en) 1993-07-02 2001-04-24 Hermann Amschler Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
NZ336202A (en) * 1996-11-11 2000-10-27 Christian R Noe Pure enantiomer aryl-cycloalkyl-hydroxycarboxylic acid esters and use in treating smooth muscle spasms and respiritory diseases
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) * 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
PT1283036E (pt) 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
BR0115016A (pt) * 2000-10-31 2005-05-03 Boehringer Ingelheim Pharma Formulação de solução inalativa com um sal de tiotrópio
GB0029903D0 (en) 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
NZ528640A (en) 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20040147544A1 (en) 2001-05-25 2004-07-29 Michael Yeadon Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
EP1397135B1 (en) 2001-05-25 2006-12-06 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
AU2003272450A1 (en) * 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
MXPA05010160A (es) 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
JPWO2005055999A1 (ja) 2003-12-08 2007-07-05 日本新薬株式会社 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1863476A1 (en) 2007-12-12
RU2420285C2 (ru) 2011-06-10
DK1863476T3 (en) 2016-05-17
CA2595791C (en) 2013-10-08
JP4991693B2 (ja) 2012-08-01
EP1863476B1 (en) 2016-02-03
RU2007138270A (ru) 2009-04-27
WO2006097250A1 (en) 2006-09-21
MX2007011273A (es) 2007-11-08
NO340405B1 (no) 2017-04-18
JP2008533072A (ja) 2008-08-21
HK1114013A1 (en) 2008-10-24
NO20075287L (no) 2007-12-05
US20060211729A1 (en) 2006-09-21
PL1863476T3 (pl) 2016-07-29
HUE027076T2 (en) 2016-08-29
NZ560206A (en) 2009-09-25
CA2595791A1 (en) 2006-09-21
ES2570332T3 (es) 2016-05-17
CY1117571T1 (el) 2017-04-26
SI1863476T1 (sl) 2016-05-31
US8268864B2 (en) 2012-09-18
AU2006224842B2 (en) 2011-09-29
AU2006224842A1 (en) 2006-09-21
CN101128196B (zh) 2013-01-02
CN101128196A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
HRP20160373T1 (hr) Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava
JP2008533072A5 (hr)
HRP20200260T1 (hr) Pripravci, postupci i sustavi za respiratornu isporuku dva ili više aktivnih sredstava
HRP20120286T1 (hr) Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
JP2007520508A5 (hr)
JP2007520507A5 (hr)
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
JP2007520506A5 (hr)
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
RU2006132038A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
JP2010132695A5 (hr)
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
SI2928889T1 (en) COMPOUNDS WITH ACTIVITY OF ANTAGONIST OF MUSCARIN RECEPTORS AND BETA2 AGENTIST ADRENERGY RECEPTORS
HRP20151214T4 (hr) Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
JP2019517597A5 (hr)
BRPI0606283A2 (pt) formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
KR20220158030A (ko) 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
ES2610104T3 (es) Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка